A novel approach on pharmacokinetic/pharmacodynamic correlations of risperidone: Understanding its safety and efficacy profiles

Acta Endocrinologica

Volumn 6, Issue 2, 2010, Pages 265-285

  Voicu, V A ^a,d   Medvedovici, A ^c   Miron, D ^b   Radulescu F ^b  

^a Toxicology and Psychopharmacology ^*  (Romania)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c UNIVERSITY OF BUCHAREST   (Romania)

^d Romanian Army Center for Medical Research   (Romania)

Author keywords

9 hydroxy risperidone; Pharmacokinetic pharmacodynamic correlations; Risperidone

Indexed keywords

EID: 79960416887     PISSN: 18410987     EISSN: None     Source Type: Journal    
DOI: 10.4183/aeb.2010.265     Document Type: Article

References (85)

1. De Buck SS, Mackie CE. Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation. Expert Opin Drug Metab Toxicol 2007; 3(6):865-878.
2. de Leon J, Sandson NB, Cozza KL. A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part I. Psychosomatics 2008; 49(3):258-270.
3. de Leon J, Sandson NB, Cozza KL. A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part II. Psychosomatics 2008; 49(4):347-361.
4. Huang ML, Van PA, Woestenborghs R, De CR, Heykants J, Jansen AA. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993; 54(3):257-268.
5. Scordo MG, Spina E, Facciola G, Avenoso A, Johansson I, Dahl ML. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) 1999; 147(3):300-305.
6. Bork JA, Rogers T, Wedlund PJ, de LJ. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry 1999; 60(7):469-476.
7. de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66(1):15-27.
8. Voicu VA, Radulescu FS, Miron DS, Mircioiu C. CYP 2D6 polymorphism and interindividual variability of drug response. A risperidone study case. Rev Med Farm Targu-Mures 2007; 53:265-270.
9. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl) 1994; 114(1):9-23.
10. Van Beijsterveldt LE, Geerts RJ, Leysen JE, Megens AA, Van den Eynde HM, Meuldermans WE, Heykants JJ. Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology (Berl) 1994; 114(1):53-62.
11. Lane HY, Chiu WC, Chou JC, Wu ST, Su MH, Chang WH. Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. J Clin Psychiatry 2000; 61(3):209-214.
12. Kalow W. Pharmacogenetics in biological perspective. Pharmacol Rev 1997; 49(4):369-379.
13. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 2001; 22(6):298-305.
14. Roden DM, George AL, Jr. The genetic basis of variability in drug responses. Nat Rev Drug Discov 2002; 1(1):37-44.
15. de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics 2010; 51(1):80-88.
16. Riedel M, Schwarz MJ, Strassnig M, Spellmann I, Muller-Arends A, Weber K, Zach J, Muller N, Moller HJ. Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci 2005; 255(4):261-268.
17. Arranz MJ, de LJ. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007; 12(8):707-747.
18. Aravagiri M, Yuwiler A, Marder SR. Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat. Psychopharmacology (Berl) 1998; 139(4):356-363.
19. Aravagiri M, Marder SR. Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. Psychopharmacology (Berl) 2002; 159(4): 424-431.
20. Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, de Morais SM. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos 2008; 36(2):268-275.
21. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004; 25(8):423-429.
22. Summerfield SG, Read K, Begley DJ, Obradovic T, Hidalgo IJ, Coggon S, Lewis AV, Porter RA, Jeffrey P. Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther 2007; 322(1):205-213.
23. Thuerauf N, Fromm MF. The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases. Eur Arch Psychiatry Clin Neurosci 2006; 256(5):281-286.
24. Mannens G, Meuldermans W, Snoeck E, Heykants J. Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology (Berl) 1994; 114(4):566-572.
25. Zhu HJ, Wang JS, Markowitz JS, Donovan JL, Gibson BB, Devane CL. Risperidone and paliperidone inhibit p-glycoprotein activity in vitro. Neuropsychopharmacology 2007; 32(4):757-764.
26. Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007; 46(5):359-388.
27. Seeman P. An update of fast-off dopamine D2 atypical antipsychotics. Am J Psychiatry 2005; 162(10):1984-1985.
28. NIMH Psychoactive Drug Screening Program, 2010. (Accessed on March 12, 2010, at site ).
29. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther 2010; 125(1):169-179.
30. Fitzgerald P, Dinan TG. Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol 2008; 22(2 Suppl):12-19.
31. Hansch C, Anderson SM. The structure-activity relationship in barbiturates and its similarity to that in other narcotics. J Med Chem 1967; 10(5):745-753.
32. Hansch C, Glave WR. Structure-activity relationships in membrane-perturbing agents. Hemolytic, narcotic, and antibacterial compounds. Mol Pharmacol 1971; 7(3):337-354.
33. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46(1-3):3-26.
34. Aravagiri M, Marder SR, Yuwiler A, Midha KK, Kula NS, Baldessarini RJ. Distribution of fluphenazine and its metabolites in brain regions and other tissues of the rat Neuropsychopharmacology 1995; 13(3):235-247.
35. Darby JK, Pasta DJ, Elfand L, Dabiri L, Clark L, Herbert J. Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J Clin Psychopharmacol 1997; 17(6):478-484.
36. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, Devane CL. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol 2004; 7(4):415-419.
37. Liu X, Chen C, Smith BJ. Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther 2008; 325(2):349-356.
38. Yasui-Furukori N, Mihara K, Takahata T, Suzuki A, Nakagami T, De VR. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br J Clin Pharmacol 2004; 57(5):569-575.
39. Bebawy M, Chetty M. Differential pharmacological regulation of drug efflux and pharmacoresistant schizophrenia. Bioessays 2008; 30(2):183-188.
40. Campbell DB. The use of kinetic-dynamic interactions in the evaluation of drugs. Psychopharmacology (Berl) 1990; 100(4):433-450.
41. Pardridge WM. Brain drug development and brain drug targeting. Pharm Res 2007; 24(9):1729-1732.
42. Fischer H, Gottschlich R, Seelig A. Blood-brain barrier permeation: molecular parameters governing passive diffusion. J Membr Biol 1998; 165(3):201-211.
43. Lloyd K, Hornykiewicz O. Parkinson's disease: activity of L-dopa decarboxylase in discrete brain regions. Science 1970; 170(963):1212-1213.
44. Hammarlund-Udenaes M, Friden M, Syvanen S, Gupta A. On the rate and extent of drug delivery to the brain. Pharm Res 2008; 25(8):1737-1750.
45. van De Waterbeemd H, Smith DA, Beaumont K, Walker DK. Property-based design: optimization of drug absorption and pharmacokinetics. J Med Chem 2001; 44(9):1313-1333.
46. Pajouhesh H, Lenz GR. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2005; 2(4):541-553.
47. Goodwin JT, Conradi RA, Ho NF, Burton PS. Physicochemical determinants of passive membrane permeability: role of solute hydrogen-bonding potential and volume. J Med Chem 2001; 44(22):3721-3729.
48. Kelder J, Grootenhuis PD, Bayada DM, Delbressine LP, Ploemen JP. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res 1999; 16(10):1514-1519.
49. The PubChem project, 2010 (Accessed March 12, 2010, at site ).
50. Leysen JE, Janssen PM, Megens AA, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 1994; 55 Suppl:5-12.
51. Schotte A, Janssen PF, Megens AA, Leysen JE. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res 1993; 631(2):191-202.
52. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van GP, Lesage AS. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.Psychopharmacology (Berl) 1996; 124(1-2):57-73.
53. Weiden PJ, Preskorn SH, Fahnestock PA, Carpenter D, Ross R, Docherty JP. Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a Roadmap. J Clin Psychiatry 2007; 68 Suppl 7:1-48.
54. Laruelle M, D'Souza CD, Baldwin RM, Abi-Dargham A, Kanes SJ, Fingado CL, Seibyl JP, Zoghbi SS, Bowers MB, Jatlow P, Charney DS, Innis RB. Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 1997; 17(3):162-174.
55. Yasui-Furukori N, Saito M, Nakagami T, Furukori H, Suzuki A, Kondo T et al. Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients. J Psychopharmacol 2009.
56. Maguire GA. Comprehensive understanding of schizophrenia and its treatment. Am J Health Syst Pharm 2002; 59(17 Suppl 5):S4-11.
57. Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 1998; 3(2):123-134.
58. Remington G, Seeman P. D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. J Clin Psychiatry 1999; 60(S10):15-19.
59. Stahl S. Describing an atypical antipsychotic: receptor binding profile and its role in pathphysiology. J Clin Psychiatry 2003; 5(S3):9-13.
60. Kapur S, Langlois X, Vinken P, Megens AA, De CR, Andrews JS. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 2002; 302(3):1129-1134.
61. Melkersson KI. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol 2006; 21:529-532.
62. Farah A. Atypicality of atypical antipsychotics. Prim Care Companion. J Clin Psychiatry 2005; 7(6):268-274.
63. Buckley PF. Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents. J Clin Psychiatry 2007; 68(S6):5-9.
64. Dolder C, Nelson M, Deyo Z. Paliperidone for schizophrenia. Am J Health Syst Pharm 2008; 65(5):403-413.
65. Montgomery J, Winterbottom E, Jessani M, Kohegyi E, Fulmer J, Seamonds B, Josiassen RC. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry 2004; 65:1491-1498.
66. Jones HM, Pilowsky LS. Dopamine and antipsychotic drug action revisited. Br J Psychiatry 2002; 181:271-275.
67. Strange PG. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 2001; 53(1):119-133.
68. Torre DL, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag 2007; 3(5):929-951.
69. Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry 2003; 182:199-204.
70. Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002; 159(1):133-135.
71. Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch RJ. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005; 162(5):1010-1012.
72. Citrome L. Paliperidone: quo vadis? Int J Clin Pract 2007; 61(4):653-662.
73. Troost PW, Lahuis BE, Hermans MH, Buitelaar JK, van EH, Scahill L et al. Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. J Clin Psychopharmacol 2007; 27(1):52-57.
74. Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol 2008; 22(2 Suppl):46-55.
75. Kramer M, Simpson G, Maciulis V, Kushner S, Vijapurkar U, Lim P, Eerdekens M. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2007; 27(1):6-14.
76. Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, Eerdekens M. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol 2009;1-13.
77. Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 2006; 31(9):1854-1863.
78. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000; 57(6):553-559.
79. Yokoi F, Grunder G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002; 27(2):248-259.
80. Tauscher J, Hussain T, Agid O, Verhoeff NP, Wilson AA, Houle S, Remington G, Zipursky RB, Kapur S. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry 2004; 161(9):1620-1625.
81. Citrome L. Paliperidone palmitate - review of the efficacy, safety and cost of a new secondgeneration depot antipsychotic medication. Int J Clin Pract 2010; 64(2):216-239.
82. Tollin SR. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest 2000; 23(11):765-770.
83. Karlsson P, Dencker E, Nyberg S. Pharmacokinetics, dopamine D2 and serotonin 5-HT2A receptor occupancy and safety profile of paliperidone extended-release in healthy subjects. 5-2-2006.
84. Frankle WG, Gil R, Hackett E, Mawlawi O, Zea-Ponce Y, Zhu Z, Kochan LD, Cangiano C, Slifstein M, Gorman JM, Laruelle M, Abi-Dargham A. Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications. Psychopharmacology (Berl) 2004; 175(4):473-480.
85. Complete application for Invega tablets. Scientific discussion, EMEA. 2007 (Accessed on March 12, 2010, at site http://www.ema.europa.eu/humandocs/PDFs/EPAR/invega/H-746-en6.pdf).